Biotech News

Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Unicycive Therapeutics (UNCY)Unicycive TherapeuticsEarnings

UNCY (UNCY) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is uncy.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

Unicycive Therapeutics

Kidney Disease Therapeutics Unicycive Therapeutics develops medicines for conditions associated with chronic kidney disease. Oxylanthanum Carbonate Oxylanthanum carbonate is an oral phosphate binder for hyperphosphatemia in dialysis patients, designed to reduce pill burden relative to existing therapies. Commercial Preparation Unicycive...

Recent company news

Stock data

Close
5.05 USD
Market cap
193.04M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States